 CytoDyn Inc said it has received a positive response from the US Food and Drug Administration FDA to conduct a Phase III randomized, double-blind, placebo-controlled trial for evaluating the efficacy and safety of leronlimab on critically ill coronavirus COVID-19 pneumonia patients. The trial will be performed in combination with the standard of care for COVID-19 pneumonia patients with the need for Invasive Mechanical Ventilation IMV or Extracorporeal Membrane Oxygenation ECMO, the company said. 